At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARVN Arvinas Holding Company LLC
Market Closed 03-27 16:00:00 EDT
10.10
-0.77
-7.08%
盘后10.10
+0.000.00%
17:26 EDT
High11.08Low9.97Vol828.75K
Open10.87D1 Closing10.87Amplitude10.21%
Mkt Cap648.67MTradable Cap648.67MTotal Shares64.22M
T/O8.44MT/O Rate1.29%Tradable Shares64.22M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arvinas Is Maintained at Buy by BTIG
Dow Jones  ·  03-19
Arvinas Is Maintained at Buy by BTIG
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
TIPRANKS  ·  03-19
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
Wells Fargo Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)
TIPRANKS  ·  03-19
Wells Fargo Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)
Arvinas price target raised to $21 from $18 at Citi
TIPRANKS  ·  03-19
Arvinas price target raised to $21 from $18 at Citi
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)
TIPRANKS  ·  03-19
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
Reuters  ·  03-19
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Reuters  ·  03-18
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker
Reuters  ·  03-18
BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker
Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14
Reuters  ·  03-18
Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14
Arvinas Announces Positive Phase 1 Data for Arv-102 Showing Greater Than 50% Lrrk2 Degradation in the Csf of Patients With Parkinson’s Disease Treated for 28 Days
THOMSON REUTERS  ·  03-18
Arvinas Announces Positive Phase 1 Data for Arv-102 Showing Greater Than 50% Lrrk2 Degradation in the Csf of Patients With Parkinson’s Disease Treated for 28 Days
Arvinas Inc: Arv-102 Was Well Tolerated Across All Dose Levels Following 28 Days of Once-Daily Dosing
THOMSON REUTERS  ·  03-18
Arvinas Inc: Arv-102 Was Well Tolerated Across All Dose Levels Following 28 Days of Once-Daily Dosing
Arvinas Inc - Plans Phase 1B Trial of Arv-102 in Psp in Q2 2026
THOMSON REUTERS  ·  03-18
Arvinas Inc - Plans Phase 1B Trial of Arv-102 in Psp in Q2 2026
Arvinas Inc - No Serious Adverse Events, Discontinuations, or Deaths Reported With Arv-102
THOMSON REUTERS  ·  03-18
Arvinas Inc - No Serious Adverse Events, Discontinuations, or Deaths Reported With Arv-102
Arvinas to Present Phase 1 ARV-102 Data at AD/PD 2026 Conference
Reuters  ·  03-11
Arvinas to Present Phase 1 ARV-102 Data at AD/PD 2026 Conference
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
TIPRANKS  ·  03-06
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Arvinas Is Maintained at Buy by Citigroup
Dow Jones  ·  03-06
Arvinas Is Maintained at Buy by Citigroup
Arvinas price target raised to $18 from $15 at Citi
TIPRANKS  ·  03-05
Arvinas price target raised to $18 from $15 at Citi
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)
TIPRANKS  ·  03-04
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley
TIPRANKS  ·  02-27
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
TIPRANKS  ·  02-26
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines

Introduction

Company Name.
Arvinas Holding Company LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Issue price:
--